Remove Big Data Remove Clinical Trials Remove Development Remove Engineer
article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. It accounts for the majority of big data in healthcare and comprises information, such as medical images, surveys, chats, and written narratives.

article thumbnail

What’s the next step in big data and AI?

Drug Discovery World

Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? His work provides insight into AI and big data in relation to pharma and drug discovery– now and in the future. AI and big data are now commonly involved with drug discovery and development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas.

article thumbnail

June 26, 2023: NIMHD Director Discusses Ways Researchers Can Help Reduce Health Disparities

Rethinking Clinical Trials

He recommended sitting down with people as equals to co-develop research. The post June 26, 2023: NIMHD Director Discusses Ways Researchers Can Help Reduce Health Disparities appeared first on Rethinking Clinical Trials. People just don’t show up because you have a good study.

Research 130
article thumbnail

Sensyne launches fundraising, agrees patient data deal with Phesi

pharmaphorum

UK digital health firm Sensyne has secured access to millions more anonymised patent records via an alliance with US clinical trial data specialist Phesi. The new agreement comes after a string of access deals with NHS trusts for patient data, and coincides with a bid by Sensyne to raise £27.5